Chong Kun Dang Pharmaceutical Stock Forecast for 2023 - 2025 - 2030
Updated on 05/02/2024
Chong Kun Dang Pharmaceutical Stock Forecast and Price Target
In recent months, four notable analysts have provided yearlong price targets for Chong Kun Dang Pharmaceutical, with the average target coming in at ₩150000.00. If it were to be achieved, this would result in a potential upside of approximately 43.82 percent from the most recent closing price in May, 2024. The high end is ₩180000.00, and the low is ₩135000.00. Even if you are not interested in A185750 stock, you should still be aware of its competitors.
43.82% Upside
Chong Kun Dang Pharmaceutical Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Chong Kun Dang Pharmaceutical's Price has gone down from ₩132.43k to ₩0.00 – a 100.00% drop. In the next year, analysts are expecting an increase in Fair Value, predicting it will reach ₩139.08k – an increase of 100.00%. The Chong Kun Dang Pharmaceutical forecast is for Fair Value to reach ₩143.61k or grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| A128940 Stock Forecast | Hanmi Pharm. | Outperform |
18
|
₩316.50k | ₩382.71k | 31.12% |
| A008930 Stock Forecast | Hanmi Science | - |
14
|
₩42.55k | ₩0.00 | -100.00% |
| A000250 Stock Forecast | Sam Chun Dang Pharm. | - |
6
|
₩104.60k | ₩80.00k | -100.00% |
| A145020 Stock Forecast | Hugel | Buy |
16
|
₩211.50k | ₩201.75k | 3.55% |
| A009420 Stock Forecast | Hanall Biopharma | Buy |
14
|
₩36.10k | ₩44.67k | 24.65% |
Chong Kun Dang Pharmaceutical Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Chong Kun Dang Pharmaceutical's Revenue has increased by 28.12%, going from ₩1.30T to ₩1.67T. In the next year, 6 analysts estimate that Chong Kun Dang Pharmaceutical's Revenue will decrease by 4.80%, reaching ₩1.59T. According to professional forecasts, in 2030, Chong Kun Dang Pharmaceutical's Revenue will decrease by 3.32%, reaching ₩1.61T.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| A019170 Stock Forecast | Shinpoong Pharmaceutical Co.,L... | - |
14
|
₩12.96k | ₩0.00 | -100.00% |
| A069620 Stock Forecast | Daewoong pharmaceutical Co.,Lt... | Buy |
16
|
₩111.90k | ₩156.10k | 42.98% |
| A005250 Stock Forecast | Green Cross Holdings | - |
16
|
₩16.17k | ₩0.00 | -100.00% |
Chong Kun Dang Pharmaceutical Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Chong Kun Dang Pharmaceutical's Dividend per Share has grown, increasing from ₩907.03 to ₩1047.62 – an increase of 15.50%. According to 6 analysts, Chong Kun Dang Pharmaceutical's Dividend per Share will fall by 7.60% in the next year, reaching ₩968.00. Professionals believe that By 2030, Chong Kun Dang Pharmaceutical's Dividend per Share will fall to ₩1018.59 – a 2.77% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| A003090 Stock Forecast | Daewoong | Outperform |
14
|
₩18.82k | ₩38.00k | 32.84% |
| A003850 Stock Forecast | Boryung | Buy |
17
|
₩11.15k | ₩13.50k | 43.50% |
| A086450 Stock Forecast | DongKook Pharmaceutical | Buy |
16
|
₩16.48k | ₩20.00k | 45.63% |
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| A001060 Stock Forecast | JW Pharmaceutical | Buy |
14
|
₩30.95k | ₩40.62k | 35.70% |
| A000640 Stock Forecast | Dong-A Socio Holdings | - |
13
|
₩110.20k | ₩0.00 | -100.00% |
| A170900 Stock Forecast | Dong-A ST | Outperform |
17
|
₩67.60k | ₩74.50k | 20.56% |
Chong Kun Dang Pharmaceutical EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Chong Kun Dang Pharmaceutical's EBITDA has grown, increasing from ₩147.72B to ₩283.63B – a growth of 92.00%. 6 analysts predict Chong Kun Dang Pharmaceutical's EBITDA will decrease by 46.40% in the next year, reaching ₩152.03B. By 2030, professionals predict that Chong Kun Dang Pharmaceutical's EBITDA will decrease by 36.58%, to ₩179.88B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| A058820 Stock Forecast | CMG Pharmaceutical | - |
14
|
₩2.24k | ₩0.00 | -100.00% |
| A140410 Stock Forecast | Mezzion Pharma | - |
6
|
₩36.55k | ₩0.00 | -100.00% |
| A102460 Stock Forecast | REYON Pharmaceutical | - |
15
|
₩15.75k | ₩0.00 | -100.00% |
Chong Kun Dang Pharmaceutical EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Chong Kun Dang Pharmaceutical's EBIT has grown by 98.97%, from ₩123.94B to ₩246.60B. For the following year, the 6 analysts predict that Chong Kun Dang Pharmaceutical's EBIT will drop by 51.53%, reaching ₩119.53B. In 2030, the professionals' prediction is that A185750's EBIT will decrease by 41.02%, reaching ₩145.45B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| A047920 Stock Forecast | HLB Pharmaceutical | - |
4
|
₩34.10k | ₩0.00 | -100.00% |
| A003000 Stock Forecast | Bukwang Pharmaceutical | - |
10
|
₩6.36k | ₩17.66k | -100.00% |
| A249420 Stock Forecast | Ildong Pharmaceutical | Outperform |
12
|
₩15.53k | ₩23.00k | 60.98% |
Chong Kun Dang Pharmaceutical EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Chong Kun Dang Pharmaceutical's EPS has gone down from ₩7081.74 to ₩0.00 – a 100.00% drop. In the next year, analysts are expecting an increase in EPS, predicting it will reach ₩7437.33 – an increase of 100.00%. The Chong Kun Dang Pharmaceutical forecast is for EPS to reach ₩7679.52 or grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| A053030 Stock Forecast | BINEX | - |
16
|
₩14.01k | ₩18.00k | -100.00% |
| A007570 Stock Forecast | Ilyang Pharmaceutical Co.,Ltd | - |
13
|
₩14.56k | ₩0.00 | -100.00% |
| A243070 Stock Forecast | Huons | Outperform |
18
|
₩34.50k | ₩45.00k | 56.52% |